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Background
The PDE5 inhibitors are emerging as novel therapeutic
tools in patients with idiopathic pulmonary arterial
hypertension (PAH). However, the response to the PDE5
inhibitors varies among patients. The PDE inhibitor aug-
ments and prolongs the vasodilator effect of NO. Thus,
therapeutic effectiveness of the PDE inhibitors relies on
the ability of pulmonary vascular endothelial cells to pro-
duce NO. Hemoglobin binds to NO with great affinity
and forms methemglobin by oxidation in the erythrocyte.
We hypothesized that methemoglobin level is correlated
positively with the capacity of NO production in pulmon-
ary vascular endothelial cells and can be used as a bio-
marker for prediction of therapeutic response to the
PDE5 inhibitors.
Methods
Twenty three idiopathic PAH patients (WHO functional
class II or III) who underwent right heart catheterization
received the PDE5 inhibitors [sildenafil (n=21), tadalafil
(n=2)]. None of them are smokers or taking endothelin
receptor antagonist. Arterial methemoglobin level was
measured before administration of the PDE5 inhibitors.
Hemodynamics were reassessed after a half year observa-
tion period (mean following period was 177.5 days).
Results
Mean methemoglobin level of the patients was 0.7±0.45 %
(normal range was 0.2 – 0.6 %). The reduction of mean
pulmonary arterial pressures (mPAP) by the PDE5 inhibi-
tors were significantly well correlated with the methemo-
globin levels (r=0.46, p=0.027). The patients with high
methemoglobin level (≥1.0%) exhibited significantly super-
ior reduction of mPAP than patients with low methemo-
globin level (15.5±5.86 mmHg vs 8.18±2.00 mmHg,
p=0.04). The reduction of pulmonary vascular resistance
also tended to superior in high methemoglobin level
group than low level group (6.41±4.08 Wood’sU n i tv s
4.56±1.30 Wood’sU n i t ,p = 0 . 1 1 ) .
Conclusion
Measuring methemoglobin level is feasible for prediction
of responder and non-responder to the PDE5 inhibitors
in patients with idiopathic PAH.
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